Abstract
Pancreatogenic diabetes is an underdiagnosed form of secondary diabetes that is lacking official management guidelines. This paper reviews the recommended management strategies with additional data on the promising novel drugs.
Disclosure
The author has received lecture fees from Sanofi Aventis, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim. The author reports no other conflicts of interest in this work.